Skip to Main Content

WASHINGTON — Regulators had something of an atypical message for the new nonprofit drug company backed by a host of the nation’s top hospitals: “What can we do to help?”

One of the executives behind the new drug maker, Civica Rx, told STAT he’d set up a Capitol Hill briefing after he fielded calls from roughly two dozen senators, all wanting to hear from the company about its plans. A meeting with the Food and Drug Administration also went far more smoothly than some industry tussles with their regulator.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED